CADL Stock Forecast: Candel Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Candel Therapeutics, Inc. is $18. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Candel Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (68): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CADL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CADL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Citigroup | Maintains | Buy | $26 → $20 |
| 13 Nov 2026 | Canaccord Genuity | Maintains | Buy | $25 → $13 |
| 13 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $23 → $18 |
| 13 Nov 2026 | Stifel | Maintains | Buy | $22 → $19 |
| 22 Oct 2026 | Jefferies | Initiates | Buy | $25 |
| 21 Sept 2026 | B of A Securities | Upgrade | Buy | $12 → $18 |
| 14 Aug 2026 | B of A Securities | Maintains | Neutral | $9.00 → $12 |
| 13 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $23 |
| 13 July 2026 | Stifel | Initiates | Buy | $22 |
| 20 Apr 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 18 Mar 2026 | Citigroup | Maintains | Buy | — |
| 13 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 Mar 2026 | Citigroup | Maintains | Buy | — |
| 8 Dec 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 21 Nov 2025 | Freedom Broker | Maintains | Buy | — |
| 14 Nov 2025 | Citigroup | Maintains | Buy | — |
| 28 Oct 2025 | Stephens & Co. | Initiates | Overweight | — |
| 21 Oct 2025 | LifeSci Capital | Initiates | Outperform | — |
| 29 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Sept 2025 | B of A Securities | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CADL.
This page is one stock. Monday covers all of them.
CADL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CADL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Candel Therapeutics, Inc. returned +14.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CADL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 3.0×
- EV / EBITDA
- —
Cheaper than 31% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −93.6%
- Return on assets
- −33.5%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Candel Therapeutics, Inc. has a market value of $402.4M and an enterprise value of $249.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$88.5M.
Diluted earnings per share, trailing twelve months: −$1.41.
Free cash flow in the twelve months to 30 June 2026: −$57.3M.
Candel Therapeutics, Inc. employs 55 people.
Data provided by Twelve Data
CADL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CADL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Candel Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CADL
What is the CADL stock price forecast for 2026-2027?
The median 12-month analyst price target for Candel Therapeutics, Inc. is $18, with estimates ranging from $11 to $29. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CADL stock a buy right now?
Of the 10 analysts covering Candel Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Candel Therapeutics, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CADL?
As at 21 Nov 2026, Candel Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (68 of 100).
Will CADL stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts is $18, and Ticker Nerd's factor model ranks Candel Therapeutics, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CADL stock forecast for 2030?
No analyst covering Candel Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CADL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $29 over the next 12 months.
How has CADL stock performed over the past year?
Candel Therapeutics, Inc. returned +14.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Candel Therapeutics, Inc. do?
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors.
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.
CEO Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. · 55 employees · United States · https://www.candeltx.com